Your browser doesn't support javascript.
loading
Utilizing Immunoglobulin G4 Immunohistochemistry for Risk Stratification in Patients with Papillary Thyroid Carcinoma Associated with Hashimoto Thyroiditis.
Haq, Faridul; Park, Gyeongsin; Jeon, Sora; Hirokawa, Mitsuyoshi; Jung, Chan Kwon.
Afiliación
  • Haq F; Department of Biomedicine and Health Sciences, The Catholic University of Korea, Seoul, Korea.
  • Park G; Cancer Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  • Jeon S; Department of Hospital Pathology, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  • Hirokawa M; Cancer Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  • Jung CK; Department of Diagnostic Pathology and Cytology, Kuma Hospital, Kobe, Japan.
Endocrinol Metab (Seoul) ; 39(3): 468-478, 2024 Jun.
Article en En | MEDLINE | ID: mdl-38766717
ABSTRACT
BACKGRUOUND Hashimoto thyroiditis (HT) is suspected to correlate with papillary thyroid carcinoma (PTC) development. While some HT cases exhibit histologic features of immunoglobulin G4 (IgG4)-related disease, the relationship of HT with PTC progression remains unestablished.

METHODS:

This cross-sectional study included 426 adult patients with PTC (≥1 cm) undergoing thyroidectomy at an academic thyroid center. HT was identified based on its typical histologic features. IgG4 and IgG immunohistochemistry were performed. Wholeslide images of immunostained slides were digitalized. Positive plasma cells per 2 mm2 were counted using QuPath and a pre-trained deep learning model. The primary outcome was tumor structural recurrence post-surgery.

RESULTS:

Among the 426 PTC patients, 79 were diagnosed with HT. With a 40% IgG4 positive/IgG plasma cell ratio as the threshold for diagnosing IgG4-related disease, a cutoff value of >150 IgG4 positive plasma cells per 2 mm2 was established. According to this criterion, 53% (43/79) of HT patients were classified as IgG4-related. The IgG4-related HT subgroup presented a more advanced cancer stage than the IgG4-non-related HT group (P=0.038). The median observation period was 109 months (range, 6 to 142). Initial assessment revealed 43 recurrence cases. Recurrence-free survival periods showed significant (P=0.023) differences, with patients with IgG4 non-related HT showing the longest period, followed by patients without HT and those with IgG4-related HT.

CONCLUSION:

This study effectively stratified recurrence risk in PTC patients based on HT status and IgG4-related subtypes. These findings may contribute to better-informed treatment decisions and patient care strategies.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Inmunoglobulina G / Neoplasias de la Tiroides / Inmunohistoquímica / Enfermedad de Hashimoto / Cáncer Papilar Tiroideo Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Endocrinol Metab (Seoul) Año: 2024 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Inmunoglobulina G / Neoplasias de la Tiroides / Inmunohistoquímica / Enfermedad de Hashimoto / Cáncer Papilar Tiroideo Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Endocrinol Metab (Seoul) Año: 2024 Tipo del documento: Article